CMS on Thursday increased Medicare payments for administering monoclonal antibodies to treat beneficiaries with COVID-19.
According to the agency, Medicare's national average payment rate will increase from $310 to $450 for most healthcare settings. In addition, CMS will pay providers $750 for in-home monoclonal antibody infusions. The changes take effect immediately.
"These higher national average payment rates reflect additional information provided to CMS about the costs of providing these services in a safe and timely manner, such as clinical staff and personal protective equipment. This action also means Medicare payments to providers and suppliers will be more aligned to their costs to administer these products," CMS said in a statement.
CMS first approved payments for monoclonal antibody infusions in November.
